her2/neu expression in wilms' tumor and correlationwith histopathologic findings

background: wilms' tumor is an emberyonal tumor arising from remnants of immature renal tissue. her2/neu is an onco-protein which mediates cellular proliferation, differentiation and survival. methods: in the current study, we analyzed her2/neu expression in 40 wilms' tumors. the clinico-demographic data of 40 patients with wilms' tumor were retrieved. immunohistochemical staining for her2/neu was performed. her2/neuimmunoreactivity was evaluated by canadian consensus 2007 scoring system. results: among the 38 specimens with epithelial component, 68.5% were positive for her2/neu, whereas there was immunoreactivity in 37% of 38 blastemal, and 12% of 31 stromal components. the her2/neu expression was significantly higher in early stages (81.5%) than in advanced stages (36.4%) in epithelial component, but not in other components. conclusion: this study suggested that her2/neuexpression is associated with epithelial cell differentiation accompanied by lower stages of tumor. no significant relationship was found between her2/neu positivity and tumor size and patient's age and gender. please cite this article as: babashahi m, mehrazma m, nasiri sj, azizi jalilian f, rezaei-tavirani m. her2/neu expression in wilms' tumor and correlationwith histopathologic findings . iran j cancer prev. 2013; 6(3):160-64. references 1. beckwith jb. renal neoplasms of childhood. in: sternberg ss, editor. diagnostic surgical pathology. new york: raven press. 1994:1741-66. 2. m. owens c, brisse hj, olsen oe, begent j, smets am. bilateral disease and new trend in wilmstumour.pediatr radiol. 2008: 38:30-39. 3. cendron m, wajsman z. http://www.e medicine .com,inc. wilms tumor excerpt. last updated: june 29,2006. 4. cho hs, mason k, ramyar kx, stanley am, gabelli sb, denney dw jr, et al. structure of the extracellular region of her2 alone and in complex with the herceptin fab. nature. 2003; 421:756-60. 5. ross js, slodkowska ea, symmans wf, pusztai l, ravdin pm , hortobagyign.the her-2 receptor and breast cancer: ten years of targeted anti-her-2therapy and personalized medicine. the oncologist .2009, 14:320-68. 6. barok m,lsola j,palyi - krekk z, nagy p, juhasz i, vereb g, et al. trastuzmab causes antibody-dependent cellular cytotoxicity mediated growth inhibitor of submicroscopic jimt-1 breast cancer xenografts despite intrinsic drug resistance. mol cancer ther. 2007; 6(7):2065-72. 7. hudis ca. trastuzmab –mechanism of action and use in clinical practice. n enjl j med. 2007; 357(1):39-51. 8. musolino a, naldi n, bortesi b, pezzuolo d, capelletti m, missale g, et al. i mmunoglobulin g fragment c receptor polymorphism and clinical efficacy of trastuzmab-based therapy in patients with her/2 neu positive metastatic breast cancer. j clinoncol. 2008; 26(11):1789-96. 9. marty m, cognetti f, maraninchi d, snyder r, mauriac l, tubiana-hulin m, et al. randomized phase ii trial of theefficacy and safety of trastuzumab combined with docetaxel in patientswith human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the m77001 studygroup. j clinoncol. 2005; 23:4265-74. 10. hanna w, o'malley fp, barnes p, berendt r, gaboury l, magliocco a, et al. updated recommendations from the canadian national consensus meeting on her2/neu testing in breast cancer. curroncol. 2007; 14(4):149-53. 11. breslow n, olshan a, beckwith jb, green dm. epidemiology of wilms tumor. med pediatroncol.1993: 21:172-81. 12. meert ap, martin b, paesmans m, berghmans t, mascaux c, verdebout jm, et al. the role of her2/ neu expression on the survival of patients with lung cancer: a systemic review of the literature. br j cancer. 2003: 89:959-65. 13. ragab sm, samaka rm, shams tm. her2/neu expression: a predictor for differentiation and survival in children withwilms tumor. patholoncol  res. 2010: 16(1):61-7. 14. salem m, kinoshita y, tajiri t, souzaki r, tatsuta k, higashi m, et al. association between the her2 expression and histological differentiation in wilms tumor. pediatrsurgint . 2006:22:891-6. 15. potti a, forseen s, koka v ,pervez h, koch m, fraimen g, et al. determination of her-2/neu overexpression and clinical predictors of survival in a cohortof 347 patients with primary malignant brain tumors. cancerinvestig. 2004; 22(4):537-44. 16. ghanem ma, van der kwast th, den hollander jc, sudaryo mk, mathoera rb, van den heuvel mm, et al. expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erbb-2 in nephroblastoma. cancer. 2001; 92(12):3120-9. 17.yokoi a ,mc crudden kw, huang j , kim es, soffer sz, frischer js, et al. human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her/2neu expressing experimental wilmstumor.jpediatr surg. 2003; 38(11):1569-73. 18. mor y, harel y, pinthus j, wax t, kaufman-francis k, fridman e, et al. the effect of herceptin, an anti-erbb2 antibody, on wilms tumor. espu meeting on thursday 27, april 2006.